<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>CYSTADANE- betaine, anhydrousÂ powder, for solutionÂ </strong><br>Jazz Pharmaceuticals, Inc.<br></p></div>
<h1>CystadaneÂ® (betaine anhydrous for oral solution)</h1>
<div class="Contents">
<div class="Section">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_1C845AA3-AA86-496B-8997-3FEFCEE8EBFD"></a><a name="section-2"></a><p></p>
<p class="First">R<span class="Sub">x</span> only</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_ID_B635C848-E629-4A48-92DD-8DF839DCD109"></a><a name="section-3"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Cystadane<span class="Sup">Â®</span> (betaine anhydrous for oral solution) is an agent for the treatment of <span class="product-label-link" type="condition" conceptid="4012934" conceptname="Homocystinuria">homocystinuria</span>. Cystadane is a white, granular, hygroscopic powder. It contains no ingredients other than anhydrous betaine. Betaine anhydrous powder is very soluble in water, soluble in methanol and ethanol, and sparingly soluble in ether.</p>
<p>The chemical name of betaine anhydrous powder is trimethylglycine. It has a molecular weight of 117.15. The structural formula is:</p>
<div class="Figure"><img alt="Image from Drug Label Content" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=05964DAE-8B84-467C-AF97-C82706A3CAD2&amp;name=cystadane-01.jpg"></div>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_ID_25EB8E56-4217-40FE-A3AF-038737BD7B41"></a><a name="section-4"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">When administered in recommended oral dosage to children or adults, Cystadane acts as a methyl group donor in the remethylation of homocysteine to methionine in patients with <span class="product-label-link" type="condition" conceptid="4012934" conceptname="Homocystinuria">homocystinuria</span>. As a result, toxic blood levels of homocysteine are reduced in these patients, usually to 20-30 percent or less of pre-treatment levels.</p>
<p>Elevated homocysteine blood levels are associated with clinical problems such as a cardiovascular <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span>, <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span>, skeletal abnormalities, and optic lens <span class="product-label-link" type="condition" conceptid="72468" conceptname="Open dislocation of jaw">dislocation</span>. Plasma levels of homocysteine were decreased in nearly all patients treated with betaine. In observational studies without concurrent controls, clinical improvement was reported by the treating physicians in about three-fourths of patients taking betaine. Many of these patients were also taking other therapies such as vitamin B<span class="Sub">6</span> (pyridoxine), vitamin B<span class="Sub">12</span> (cobalamin), and folate with variable biochemical responses. In most cases studied, adding betaine resulted in a further reduction of homocysteine.</p>
<p>Betaine was observed to lower plasma homocysteine levels in the three types of <span class="product-label-link" type="condition" conceptid="4012934" conceptname="Homocystinuria">homocystinuria</span>, i.e., cystathionine beta-synthase (CBS) deficiency; 5,10-methylenetetrahydrofolate reductase (MTHFR) deficiency; and cobalamin cofactor metabolism (<span class="Italics">cbl</span>) defect.</p>
<p>Betaine has also been demonstrated to increase low plasma methionine and S-adenosylmethionine (SAM) levels in patients with MTHFR deficiency and <span class="Italics">cbl</span> defect.</p>
<p>In CBS-deficient patients, large increases in methionine levels over baseline have been observed.</p>
<p>Betaine occurs naturally in the body. It is a metabolite of choline and is present in small amounts in foods such as beets, spinach, cereals, and seafood.</p>
<p>Pharmacokinetic studies of betaine are not available. Plasma levels of betaine have not been measured in patients and have not been correlated to homocysteine levels. However, pharmacodynamic measurements, i.e., monitoring of plasma homocysteine levels, have demonstrated that the onset of action of betaine is within several days and that a steady state in response to dosage is achieved within several weeks. Patients have taken betaine for many years without evidence of tolerance.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_ID_0D7B8938-C313-4E18-A371-23FA7F744687"></a><a name="section-5"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">Cystadane (betaine anhydrous for oral solution) is indicated for the treatment of <span class="product-label-link" type="condition" conceptid="4012934" conceptname="Homocystinuria">homocystinuria</span> to decrease elevated homocysteine blood levels. Included within the category of <span class="product-label-link" type="condition" conceptid="4012934" conceptname="Homocystinuria">homocystinuria</span> are deficiencies or defects in:</p>
<ol>
<li>cystathionine beta-synthase (CBS),</li>
<li>5,10-methylenetetrahydrofolate reductase (MTHFR),</li>
<li>cobalamin cofactor metabolism (<span class="Italics">cbl</span>).</li>
</ol>
<p>Patient response to Cystadane can be monitored by homocysteine plasma levels (see <a href="#i4i_dosage_admin_ID_AD9A16DE-DF93-469C-9B29-EAC8B6B7D5E3">DOSAGE AND ADMINISTRATION</a>). Response usually occurs within a week and steady state within a month.</p>
<p>Cystadane has been administered concomitantly with vitamin B<span class="Sub">6</span> (pyridoxine), vitamin B<span class="Sub">12</span> (cobalamin), and folate.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="i4i_precautions_ID_0B07D5FE-49F6-4725-9F3B-D92ECCDBB351"></a><a name="section-6"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="i4i_precautions_general_ID_BA741C88-FBE0-4271-841F-179AA09638A1"></a><a name="section-6.1"></a><p></p>
<h2>General</h2>
<p class="First">Therapy with Cystadane should be directed by physicians knowledgeable in the management of patients with <span class="product-label-link" type="condition" conceptid="4012934" conceptname="Homocystinuria">homocystinuria</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_05C660FE-48CD-45F7-8C3E-2D0E21765B2E"></a><a name="section-6.2"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4182278" conceptname="Hypermethioninemia">Hypermethioninemia</span></h2>
<p class="First">Patients with <span class="product-label-link" type="condition" conceptid="4012934" conceptname="Homocystinuria">homocystinuria</span> due to cystathionine beta-synthase (CBS) deficiency may also have elevated plasma methionine concentrations. Treatment with Cystadane may further increase methionine concentrations due to the remethylation of homocysteine to methionine. <span class="product-label-link" type="condition" conceptid="376690" conceptname="Cerebral edema">Cerebral edema</span> has been reported in patients with <span class="product-label-link" type="condition" conceptid="4182278" conceptname="Hypermethioninemia">hypermethioninemia</span>, including a few patients treated with Cystadane. Plasma methionine concentrations should be monitored in patients with CBS deficiency. Plasma methionine concentrations should be kept below 1,000 umol/L through dietary modification and, if necessary, a reduction of Cystadane dose.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="i4i_info_patients_ID_8BD45CFA-6952-420E-9161-4AB6789514F0"></a><a name="section-6.3"></a><p></p>
<h2>Information for patients</h2>
<ol>
<li>Shake bottle lightly before removing cap.</li>
<li>Measure with the scoop provided.</li>
<li>One level scoop (1.7 cc) is equivalent to 1 gram of betaine anhydrous powder. Measure the number of scoops your physician has prescribed.</li>
<li>Mix with 4 to 6 ounces (120 to 180 mL) of water, juice, milk, or formula until completely dissolved, or mix with food, then ingest immediately.</li>
</ol>
<p class="First">Always replace the cap tightly after using. Protect from moisture.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_ID_591690BC-A859-407D-984C-85A3F5875259"></a><a name="section-6.4"></a><p></p>
<h2>Carcinogenesis, mutagenesis, impairment of fertility</h2>
<p class="First">Long-term carcinogenicity and fertility studies have not been conducted on betaine. No evidence of genotoxicity was demonstrated in the following tests: Metaphase Analysis of Human <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">Lymphocytes</span>; Bacterial Reverse Mutation Assay; and Mouse Micronucleus Test.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_ID_7B4E33A1-0F8C-4533-8174-9BC103652AD9"></a><a name="section-6.5"></a><p></p>
<h2>Pregnancy</h2>
<p class="First">Pregnancy Category C. Animal reproduction studies have not been conducted with betaine. It is also not known whether betaine can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Cystadane (betaine anhydrous for oral solution) should be given to a pregnant woman only if clearly needed.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_ID_E91529F8-BF85-40CC-805C-4076AB571041"></a><a name="section-6.6"></a><p></p>
<h2>Nursing mothers</h2>
<p class="First">It is not known whether betaine is excreted in human milk (although its metabolic precursor, choline, occurs at high levels in human milk). Because many drugs are excreted in human milk, caution should be exercised when Cystadane is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_ID_9C12A523-C7D5-47D4-9F46-A8EED0D4FF48"></a><a name="section-6.7"></a><p></p>
<h2>Pediatric use</h2>
<p class="First">The majority of case studies of <span class="product-label-link" type="condition" conceptid="4012934" conceptname="Homocystinuria">homocystinuria</span> patients treated with betaine have been pediatric patients. The disorder, in its most severe form, can be manifested within the first months or years of life by <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, <span class="product-label-link" type="condition" conceptid="437986" conceptname="Failure to thrive">failure to thrive</span>, <span class="product-label-link" type="condition" conceptid="436077" conceptname="Developmental delay">developmental delays</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, or optic lens displacement. Patients have been treated successfully without adverse effects within the first months or years of life with dosages of 6 grams per day or more of betaine with resultant biochemical and clinical improvement. However, dosage titration may be preferable in pediatric patients (see <a href="#i4i_dosage_admin_ID_AD9A16DE-DF93-469C-9B29-EAC8B6B7D5E3">DOSAGE AND ADMINISTRATION</a>).</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_ID_C1124D70-BE74-49D2-B830-33EFD3D51028"></a><a name="section-7"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">Adverse reactions to betaine have been minimal. In a survey study of physicians who had treated a total of 111 <span class="product-label-link" type="condition" conceptid="4012934" conceptname="Homocystinuria">homocystinuria</span> patients with betaine, the types of adverse effects and the number of patients experiencing them were as follows:</p>
<a name="ID_439E6994-DC89-45DF-B304-64B67C2A4B55"></a><table border="single" frame="box" width="360.79999999999995">
<col width="33.315%">
<col width="4.850%">
<col width="56.984%">
<col width="4.850%">
<tbody class="Headless">
<tr class="First">
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td align="left" valign="top">2</td>
<td align="left" valign="top">â€œCaused odorâ€?</td>
<td align="left" valign="top">1</td>
</tr>
<tr>
<td align="left" valign="top">GI distress</td>
<td align="left" valign="top">2</td>
<td align="left" valign="top">Questionable psychological changes</td>
<td align="left" valign="top">1</td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td align="left" valign="top">1</td>
<td align="left" valign="top">â€œAspirated the powderâ€?</td>
<td align="left" valign="top">1</td>
</tr>
<tr class="Last">
<td align="left" valign="top">Unspecified problem</td>
<td align="left" valign="top">1</td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
</tr>
</tbody>
</table>
<p>A few cases of <span class="product-label-link" type="condition" conceptid="376690" conceptname="Cerebral edema">cerebral edema</span> have been reported secondary to severe <span class="product-label-link" type="condition" conceptid="4182278" conceptname="Hypermethioninemia">hypermethioninemia</span> in patients with cystathionine beta-synthase (CBS) deficiency treated with Cystadane. See <a href="#i4i_precautions_ID_0B07D5FE-49F6-4725-9F3B-D92ECCDBB351">PRECAUTIONS</a>: <a href="#i4i_section_ID_05C660FE-48CD-45F7-8C3E-2D0E21765B2E"><span class="product-label-link" type="condition" conceptid="4182278" conceptname="Hypermethioninemia">Hypermethioninemia</span></a>.</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_ID_7C2B6C93-931E-4110-B26A-D1025E0C672D"></a><a name="section-8"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">In an acute toxicology study in rats, <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> frequently occurred at doses equal to or greater than 10,000 mg/kg.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_ID_AD9A16DE-DF93-469C-9B29-EAC8B6B7D5E3"></a><a name="section-9"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">The usual dosage used in adult and pediatric patients is 6 grams per day administered orally in divided doses of 3 grams two times per day. Dosages of up to 20 grams per day have been necessary to control homocysteine levels in some patients. In pediatric patients less than 3 years of age, dosage may be started at 100 mg/kg/day and then increased weekly by 50 mg/kg increments. In one study by Matthews<span class="Sup">i</span> et al., pharmacokinetic and pharmacodynamic simulation indicated minimal benefit from exceeding a twice-daily dosing schedule and a 150 mg/kg/day dosage for betaine. Dosage in all patients can be gradually increased until plasma total homocysteine is undetectable or present only in small amounts. Plasma methionine concentrations should be monitored in patients with CBS-deficiency. See <a href="#i4i_precautions_ID_0B07D5FE-49F6-4725-9F3B-D92ECCDBB351">PRECAUTIONS</a>: <a href="#i4i_section_ID_05C660FE-48CD-45F7-8C3E-2D0E21765B2E"><span class="product-label-link" type="condition" conceptid="4182278" conceptname="Hypermethioninemia">Hypermethioninemia</span></a>.</p>
<p>The prescribed amount of Cystadane (betaine anhydrous for oral solution) should be measured with the measuring scoop provided (one level 1.7 cc scoop is equal to 1 gram of betaine anhydrous powder) and then dissolved in 4 to 6 ounces (120 to 180 mL) of water, juice, milk, or formula, or mixed with food for immediate ingestion.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_ID_D09576D9-5E78-42F2-BE9A-81AE015F31C3"></a><a name="section-10"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">Cystadane is available in plastic bottles containing 180 grams of betaine anhydrous. Each bottle is equipped with a plastic child-resistant cap and is supplied with a polystyrene measuring scoop. One level scoop (1.7 cc) is equal to 1 gram of betaine anhydrous powder.</p>
<p>NDC 68727-400-01</p>
<p>180g/bottle</p>
<p>DIN 02238526</p>
<p>Store at room temperature, 15Â° - 30Â°C (59Â° - 86Â°F).</p>
<p>For questions of a medical nature in the U.S. or Canada, call <br>1-888-867-7426.</p>
<p>Cystadane<span class="Sup">Â®</span> can be ordered by calling Jazz Pharmaceuticals, Inc. Customer Service at 1-800-359-4304 or by contacting your local wholesaler.</p>
<p><span class="Bold">Distributed in the U.S. by:</span></p>
<p>Jazz Pharmaceuticals, Inc.</p>
<p>Palo Alto, CA 94304</p>
<p><span class="Bold">Distributed in Canada by:</span></p>
<p>Jazz Pharmaceuticals, Inc.</p>
<p>Scarborough, Ontario</p>
<p>M1H 2W4</p>
<p>Revision Date: August 2006</p>
<p>Part No. CYS PI-8585</p>
<p><span class="Sup">i</span>Â <span class="Underline">Matthews A, Johnson TN, Rostami-Hodjegan A, Chakrapani A, et al. An indirect response model of homocysteine suppression by betaine: optimizing the dosage regimen of betaine in <span class="product-label-link" type="condition" conceptid="4012934" conceptname="Homocystinuria">homocystinuria</span>. Br J Clin Pharmacol 2002; 54:140-146.</span></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>CYSTADANEÂ 		
					</strong><br><span class="contentTableReg">betaine, anhydrous powder, for solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:68727-400</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>betaine, anhydrous</strong> (betaine, anhydrous) </td>
<td class="formItem"></td>
<td class="formItem">180Â g Â inÂ 1Â g</td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:68727-400-01</td>
<td class="formItem">180 g in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>Jazz Pharmaceuticals, Inc.</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 3/2007<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>7D587A24-732D-934E-FCA3-381D68D37BBC</div>
<div>Set id: 05964DAE-8B84-467C-AF97-C82706A3CAD2</div>
<div>Version: 1</div>
<div>Effective Time: 20070331</div>
</div>
</div>Â <div class="DistributorName">Jazz Pharmaceuticals, Inc.</div></p>
</body></html>
